• What is ALK?
  • ALK in Anaplastic Large Cell Lymphoma
  • Clinical Trials


The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is aberrant in a variety of malignancies. For example, activating missense mutations within full length ALK are found in a subset of neuroblastomas (Chen et al. 2008; George et al. 2008; Janoueix-Lerosey et al. 2008; Mosse et al. 2008). By contrast, ALK fusions are found in anaplastic large cell lymphoma (e.g., NPM-ALK; Morris et al. 1994), colorectal cancer (Lin et al. 2009​Lipson et al. 2012), inflammatory myofibroblastic tumor (IMT; Lawrence et al. 2000) non-small cell lung cancer (NSCLC; Choi et al. 2008; Koivunen et al. 2008; Rikova et al. 2007; Soda et al. 2007; Takeuchi et al. 2009), and ovarian cancer (Ren et al. 2012). All ALK fusions contain the entire ALK tyrosine kinase domain. To date, those tested biologically possess oncogenic activity in vitro and in vivo (Choi et al. 2008; Morris et al. 1994; Soda et al. 2007; Takeuchi et al. 2009). ALK fusions and copy number gains have been observed in renal cell carcinoma (Debelenko et al. 2011; Sukov et al. 2012). Finally, ALK copy number and protein expression aberrations have also been observed in rhabdomyosarcoma (van Gaal et al. 2012).

The various N-terminal fusion partners promote dimerization and therefore constitutive kinase activity (for review, see Mosse, Wood, and Maris 2009). Signaling downstream of ALK fusions results in activation of cellular pathways known to be involved in cell growth and cell proliferation (Figure 1).


Figure 1.
Schematic representation of ALK fusions. "X" represents the various fusion partners that have been described. Dimerization of the ALK fusion mediated by the fusion partner ("X"), results in constitutive activation of the ALK tyrosine kinase. ALK signaling results in pro-growth and anti-apoptosis.

Related Pathways

Contributors: Christine M. Lovly, M.D., Ph.D., Leora Horn, M.D., M.Sc., William Pao, M.D., Ph.D. (through April 2014)

Suggested Citation: Lovly, C., L. Horn, W. Pao. 2015. ALK. My Cancer Genome https://www.padiracinnovation.org/content/disease/anaplastic-large-cell-lymphoma/alk/?tab=0 (Updated December 7).

Last Updated: December 7, 2015

ALK in Anaplastic Large Cell Lymphoma

ALK is expressed in 50–85% of ALCLs (Merkel et al. 2011). ). In 72–85% of these ALK-positive ALCLs, a translocation results in ALK fusions with NPM1; ALK fusion partners that have been found in the remaining 15–28% include TPM3, TPM4, TFG, ATIC, CLTC, MSN, MYH9, and ALO17 (RNF213; Damm-Welk et al. 2009; Falini and Martelli 2009; Moritake et al. 2011; Stein et al. 2000; Tort et al. 2001).

ALK positive ALCL has a better prognosis than ALK negative ALCL, and it is diagnosed more frequently in younger patients (Ferreri et al. 2012; Merkel et al. 2011). Use of ALK inhibitors such as crizotinib in the treatment of ALCL is being investigated.

Contributors: Valerie Brown, M.D., Ph.D., Scott C. Borinstein, M.D., Ph.D., Debra Friedman, M.D.

Suggested Citation: Brown, V., S. Borinstein, D. Friedman. 2013. ALK in Anaplastic Large Cell Lymphoma. My Cancer Genome https://www.padiracinnovation.org/content/disease/anaplastic-large-cell-lymphoma/alk/ (Updated March 6).

Last Updated: March 6, 2013

My Cancer Genome has released its new and improved cancer clinical trials search tool on our beta website. Please visit beta.padiracinnovation.org to check it out!

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.